Histological and Comparative Transcriptome Analyses Provide Insights into Small Intestine Health in Diarrheal Piglets af...
bacteria interactions.
Use of oral cholera vaccine as a vaccine probe to determine the burden of culture-negative cholera.
...
Use of oral cholera vaccine as a vaccine probe to determine the burden of culture-negative cholera.
...
Genomic plasticity associated with antimicrobial resistance in Vibrio cholerae.
...
DBT India
EVALUATION OF CARBOHYDRATE AND FIBER CONSUMPTION IN PATIENTS WITH IRRITABLE BOWEL SYNDROME IN OUTPATIENT TREATMENT
ABSTRACT BACKGROUND: Irritable bowel syndrome (IBS) is a chronic functional condition, which main symptoms of pain, discomfort and abdominal distension, constipation, diarrhea, altered fecal consistency and sensation of incomplete evacuation can be influenced by the presence of dietary fiber and fermentable carbohydrates (FODMAPs). This study aimed...
EVALUATION OF CARBOHYDRATE AND FIBER CONSUMPTION IN PATIENTS WITH IRRITABLE BOWEL SYNDROME IN OUTPATIENT TREATMENT
ABSTRACT BACKGROUND: Irritable bowel syndrome (IBS) is a chronic functional condition, which main symptoms of pain, discomfort and abdominal distension, constipation, diarrhea, altered fecal consistency and sensation of incomplete evacuation can be influenced by the presence of dietary fiber and fermentable carbohydrates (FODMAPs). This study aimed...
Parasitos gastrintestinais em filhotes caninos domiciliados do município de Araçatuba – São Paulo
Gastrointestinal parasites are common in pets. Pets play an important role among humans and lately they have been considered members of families Due to the fact of the closely contact between humans and animals, veterinarians worries about zoonotic risk of some parasitic diseases and to promote better life quality for both pets and tutors. Some gas...
Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive...
BackgroundTrastuzumab is the mainstay of therapy for patients with HER2-positive breast and gastric cancer but resistance frequently occurs. Afatinib, an irreversible oral ErbB family blocker, shows clinical activity in trastuzumab-refractory HER2-positive metastatic breast cancer.Materials and methodsThis phase I study used a modified 3 + 3 dose e...
Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive...
BackgroundTrastuzumab is the mainstay of therapy for patients with HER2-positive breast and gastric cancer but resistance frequently occurs. Afatinib, an irreversible oral ErbB family blocker, shows clinical activity in trastuzumab-refractory HER2-positive metastatic breast cancer.Materials and methodsThis phase I study used a modified 3 + 3 dose e...
Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive...
BackgroundTrastuzumab is the mainstay of therapy for patients with HER2-positive breast and gastric cancer but resistance frequently occurs. Afatinib, an irreversible oral ErbB family blocker, shows clinical activity in trastuzumab-refractory HER2-positive metastatic breast cancer.Materials and methodsThis phase I study used a modified 3 + 3 dose e...
